Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
Go back to Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026| Apogee Robotics (NASDAQ: APGE) | Delayed: 134.29 +0.03 (0.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $134.26 | 52 Week High | $0.02 | |||
| Open | $134.25 | 52 Week Low | $0.02 | |||
| Day High | $134.35 | P/E | N/A | |||
| Day Low | $134.21 | EPS | $0.00 | |||
| Volume | 289,274 | |||||
